Omega Pharma NV - SWOT, Strategy and Corporate Finance Report
Published: June 2013 · Publisher: MarketLine
Omega Pharma NV - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc.
- Description
- Table of Contents
- Ask a Question
Omega Pharma NV - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.
Features:
- Detailed information on Omega Pharma NV required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Omega Pharma NV in the form of a SWOT analysis
- An in-depth view of the business model of Omega Pharma NV including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Omega Pharma NV
- Intelligence on Omega Pharma NVnv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Omega Pharma NV, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
Omega Pharma (Omega or the 'company'), a majority owned by Couckinvest NV, is a limited liability company engaged in the development, marketing and sales of over-the-counter (OTC) pharmaceutical products. The company provides cough and cold therapies; pain relief products; vitamins, minerals, and nutritional supplements; products for gastro-intestinal disorders; skin care products; anti-allergy products; and smoking cessation therapies. It also offers anti-mosquito products, slimming products, and home diagnostics. The company primarily operates in Europe. It is headquartered in Nazareth, Belgium, and employs about 2,500 people. The company recorded revenues of E1,041.9 million ($1,339.7 million*) during the financial year ended December 2012 (FY2012), an increase of 15.7% over FY2011. The operating profit of the company was E124 million ($159.4 million*) in FY2012, an increase of 53.5% over FY2011. The net profit was E66 million ($84.9 million*) in FY2012, an increase of 83.8% over FY2011. *Calculated using a constant conversion rate of E1 = $1.2858 for the financial year ended December 31, 2012.
Reasons to Purchase:
- Gain understanding of Omega Pharma NV and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Omega Pharma NV as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Omega Pharma NV’s business structure, strategy and prospects
Features:
- Detailed information on Omega Pharma NV required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Omega Pharma NV in the form of a SWOT analysis
- An in-depth view of the business model of Omega Pharma NV including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Omega Pharma NV
- Intelligence on Omega Pharma NVnv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Omega Pharma NV, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
Omega Pharma (Omega or the 'company'), a majority owned by Couckinvest NV, is a limited liability company engaged in the development, marketing and sales of over-the-counter (OTC) pharmaceutical products. The company provides cough and cold therapies; pain relief products; vitamins, minerals, and nutritional supplements; products for gastro-intestinal disorders; skin care products; anti-allergy products; and smoking cessation therapies. It also offers anti-mosquito products, slimming products, and home diagnostics. The company primarily operates in Europe. It is headquartered in Nazareth, Belgium, and employs about 2,500 people. The company recorded revenues of E1,041.9 million ($1,339.7 million*) during the financial year ended December 2012 (FY2012), an increase of 15.7% over FY2011. The operating profit of the company was E124 million ($159.4 million*) in FY2012, an increase of 53.5% over FY2011. The net profit was E66 million ($84.9 million*) in FY2012, an increase of 83.8% over FY2011. *Calculated using a constant conversion rate of E1 = $1.2858 for the financial year ended December 31, 2012.
Reasons to Purchase:
- Gain understanding of Omega Pharma NV and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Omega Pharma NV as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Omega Pharma NV’s business structure, strategy and prospects
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Company Snapshot
Omega Pharma NV: Company Overview
Omega Pharma NV: Overview and Key Facts
Omega Pharma NV: Overview
Omega Pharma NV: Key Facts
Omega Pharma NV: Key Employees
Omega Pharma NV: Key Employee Biographies
Omega Pharma NV: Major Products and Services
Omega Pharma NV: Company History
Omega Pharma NV: Management Statement
Omega Pharma NV: Locations and Subsidiaries
Omega Pharma NV: Key Competitors
Omega Pharma NV: Company Analysis
Omega Pharma NV: Business Description
Omega Pharma NV: SWOT Analysis
Omega Pharma NV: SWOT Overview
Omega Pharma NV: Strengths
Omega Pharma NV: Weaknesses
Omega Pharma NV: Opportunities
Omega Pharma NV: Threats
Omega Pharma NV: Corporate Financial Deals Activity
Omega Pharma NV: Financial Deals Overview
Omega Pharma NV: Targets and Partners
Omega Pharma NV: Top Deals 2009 - 2013YTD*
Omega Pharma NV: Advisors
Omega Pharma NV: Top Legal Advisors
Omega Pharma NV: Mergers and Acquisitions
Omega Pharma NV: Partnership
Omega Pharma NV: Divestments
Omega Pharma NV: Private Equity and Ownership
Appendix
Contact Us
Methodology
Definitions
List of Tables
Table 1: Omega Pharma NV: Key Facts
Table 2: Omega Pharma NV: Key Employees
Table 4: Omega Pharma NV: Key Competitors
Table 5: Omega Pharma NV: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Table 6: Omega Pharma NV: M&A Average Deal Size - Value (US$m)
Table 7: Omega Pharma NV: Targets and Partners
Table 8: Omega Pharma NV: Top Deals 2009 - 2013YTD*
Table 9: Omega Pharma NV: Legal Advisor Ranking by Value (US$m)
Table 10: Omega Pharma NV: M&A Volume and Value Trend (2009 - YTD*2013)
Table 11: Omega Pharma NV: M&A Activity by Geography (2009 - YTD*2013)
Table 12: Omega Pharma NV: Partnership Volume and Value Trend (2009 - YTD*2013)
Table 13: Omega Pharma NV: Partnership Trend by Deal Type (2009 - YTD*2013)
Table 14: Omega Pharma NV: Divestments Volume and Value Trend (2009 - YTD*2013)
Table 15: Omega Pharma NV: Divestments by Geography (2009 - YTD*2013)
Table 16: Omega Pharma NV: Private Equity and Ownership Volume and Value Trend (2009 - YTD*2013)
Table 17: Omega Pharma NV: Private Equity and Ownership Volume by Deal Type (2009 - YTD*2013)
List of Figures
Figure 1: Omega Pharma NV: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Figure 2: Omega Pharma NV: M&A Average Deal Size - Value (US$m)
Figure 3: Omega Pharma NV: M&A Volume and Value Trend (2009 - YTD*2013)
Figure 4: Omega Pharma NV: M&A Activity by Geography (2009 - YTD*2013)
Figure 5: Omega Pharma NV: Partnership Volume and Value Trend (2009 - YTD*2013)
Figure 6: Omega Pharma NV: Partnership Trend by Deal Type (2009 - YTD*2013)
Figure 7: Omega Pharma NV: Divestments Volume and Value Trend (2009 - YTD*2013)
Figure 8: Omega Pharma NV: Divestments by Geography (2009 - YTD*2013)
Figure 9: Omega Pharma NV: Private Equity and Ownership Volume and Value Trend (2009 - YTD*2013)
Figure 10: Omega Pharma NV: Private Equity and Ownership Volume by Deal Type (2009 - YTD*2013)
Omega Pharma NV: Company Overview
Omega Pharma NV: Overview and Key Facts
Omega Pharma NV: Overview
Omega Pharma NV: Key Facts
Omega Pharma NV: Key Employees
Omega Pharma NV: Key Employee Biographies
Omega Pharma NV: Major Products and Services
Omega Pharma NV: Company History
Omega Pharma NV: Management Statement
Omega Pharma NV: Locations and Subsidiaries
Omega Pharma NV: Key Competitors
Omega Pharma NV: Company Analysis
Omega Pharma NV: Business Description
Omega Pharma NV: SWOT Analysis
Omega Pharma NV: SWOT Overview
Omega Pharma NV: Strengths
Omega Pharma NV: Weaknesses
Omega Pharma NV: Opportunities
Omega Pharma NV: Threats
Omega Pharma NV: Corporate Financial Deals Activity
Omega Pharma NV: Financial Deals Overview
Omega Pharma NV: Targets and Partners
Omega Pharma NV: Top Deals 2009 - 2013YTD*
Omega Pharma NV: Advisors
Omega Pharma NV: Top Legal Advisors
Omega Pharma NV: Mergers and Acquisitions
Omega Pharma NV: Partnership
Omega Pharma NV: Divestments
Omega Pharma NV: Private Equity and Ownership
Appendix
Contact Us
Methodology
Definitions
List of Tables
Table 1: Omega Pharma NV: Key Facts
Table 2: Omega Pharma NV: Key Employees
Table 4: Omega Pharma NV: Key Competitors
Table 5: Omega Pharma NV: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Table 6: Omega Pharma NV: M&A Average Deal Size - Value (US$m)
Table 7: Omega Pharma NV: Targets and Partners
Table 8: Omega Pharma NV: Top Deals 2009 - 2013YTD*
Table 9: Omega Pharma NV: Legal Advisor Ranking by Value (US$m)
Table 10: Omega Pharma NV: M&A Volume and Value Trend (2009 - YTD*2013)
Table 11: Omega Pharma NV: M&A Activity by Geography (2009 - YTD*2013)
Table 12: Omega Pharma NV: Partnership Volume and Value Trend (2009 - YTD*2013)
Table 13: Omega Pharma NV: Partnership Trend by Deal Type (2009 - YTD*2013)
Table 14: Omega Pharma NV: Divestments Volume and Value Trend (2009 - YTD*2013)
Table 15: Omega Pharma NV: Divestments by Geography (2009 - YTD*2013)
Table 16: Omega Pharma NV: Private Equity and Ownership Volume and Value Trend (2009 - YTD*2013)
Table 17: Omega Pharma NV: Private Equity and Ownership Volume by Deal Type (2009 - YTD*2013)
List of Figures
Figure 1: Omega Pharma NV: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Figure 2: Omega Pharma NV: M&A Average Deal Size - Value (US$m)
Figure 3: Omega Pharma NV: M&A Volume and Value Trend (2009 - YTD*2013)
Figure 4: Omega Pharma NV: M&A Activity by Geography (2009 - YTD*2013)
Figure 5: Omega Pharma NV: Partnership Volume and Value Trend (2009 - YTD*2013)
Figure 6: Omega Pharma NV: Partnership Trend by Deal Type (2009 - YTD*2013)
Figure 7: Omega Pharma NV: Divestments Volume and Value Trend (2009 - YTD*2013)
Figure 8: Omega Pharma NV: Divestments by Geography (2009 - YTD*2013)
Figure 9: Omega Pharma NV: Private Equity and Ownership Volume and Value Trend (2009 - YTD*2013)
Figure 10: Omega Pharma NV: Private Equity and Ownership Volume by Deal Type (2009 - YTD*2013)
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.